Biosidus
Highly Engaged Employees
Manufacturing · Argentina · 201-500 Employees
View Company Info for Free
Overview
Headquarters
4234 Constitución 2841, Buenos Aires, Bu...Phone Number
+54 1149098000Website
www.biosidus.com.arRevenue
$82.5 MillionIndustry
About Biosidus
Biosidus Org Chart
Is Biosidus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Biosidus
Click to see if Biosidus had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Biosidus is spiking on competitors!
Earning: See what the market has to say on Biosidus recently announced quarterly report
Biosidus, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Biosidus has new funding data
Product Launch: Get notified when Biosidus launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Biosidus has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Biosidus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biosidus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biosidus.
Biosidus Tech Stack
A closer look at the technologies used by Biosidus
Biosidus News & Media
Biosidus Announces Promising Interim Results from Phase III Study on Agalsidase Beta for Fabry Disease
BUENOS AIRES, Argentina, April 16, 2025 (GLOBE NEWSWIRE) -- Biosidus, an Argentinean pioneer company in biotechnology research, development, and the production of high-quality biosimilars, has announced encouraging interim results from the Phase III SMILE1 study. After 26 weeks of treatment, the study successfully met its primary endpoint, underscoring the potential of agalsidase beta as a safe and effective biosimilar treatment for Fabry disease. The complete dataset, including final secondarymAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease
MADRID, Feb. 5, 2024 /PRNewswire/ -- mAbxience, a leading company in the development and manufacture of biopharmaceutical products, and part of the Fresenius Kabi and Insud Pharma groups, has announced today an important agreement with Biosidus, a renowned Argentine company specialized in...ACON and Humus Capital acquire Biosidus
ACON Investments and Humus Capital Partners have acquired a majority stake in Biosidus, an Argentina-based maker of biosimilar pharmaceuticals. No financial terms were disclosed.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biosidus
Biosidus is a leader in biosimilars within emerging markets, particularly in Latin America, with a growing presence in Asia, Africa, and Eastern Europe. The company is committed to maintaining international quality standards in its processes and products, aimed at ensuring patient health. Additionally, Biosidus offers patient support programs and p... Read More